阿罗洛尔治疗原发性高血压的Meta分析

J4 ›› 2009, Vol. 35 ›› Issue (5): 949-954.

阿罗洛尔治疗原发性高血压的Meta分析

杜冰¹, 秦玲¹, 崔文鹏²

(1.吉林大学第一医院二部心内科|吉林长春 130031；2.吉林大学第二医院肾内科|吉林长春 130041）

收稿日期:2009-03-03 出版日期:2009-09-28 发布日期:2009-10-13
通讯作者: 秦玲 E-mail:qinling@medmail.com.cn
作者简介:杜冰（1983－）|女|吉林省长春市人|医学硕士|主要从事高血压病的研究。
基金资助:
吉林省科技厅科研基金资助课题（20050408）

Mata analysis on arotinolol in treatment of essential hypertension

DU Bing, QIN Ling, CUI Wen-Feng

(1.Department of Cardiology|Second Part of First Hospital|Jilin University|Changchun 130031|China；2. Department of Nephrology|Second Hospital|Jilin University|Changchun 130041|China)

Received:2009-03-03 Online:2009-09-28 Published:2009-10-13

摘要/Abstract

摘要：

目的：利用Meta分析方法探讨阿罗洛尔治疗原发性高血压的有效性及安全性。方法：计算机检索Cochrane图书馆临床对照试验资料库(2008年第3期)、MEDLINE(1991—2009年3月)、EMbase(1991年1月—　2009年3月)、CBMdisc (1991年1月—2009年3月)、CNKI (1994年1月—2009年3月)以及手工检索关于阿罗洛尔治疗原发性高血压的相关文献，在严格质量评价的基础上，应用RevMan 4.2软件对数据进行Meta分析。结果：共初检出176篇文献，经筛选最终纳入6篇8项关于阿罗洛尔与其他常用抗高血压药治疗原发性高血压的文献。同质性检验，有效性：χ2=4.41，df=7，P=0.73；安全性：χ2=2.96，df=4，P=0.56。二者合并效应量的估计，有效性：Z=0.64（P=0.52），合并OR=1.17，OR95％CI (0.72～1.85)；安全性：Z=1.75（P=0.08），合并OR=0.60，OR95％CI (0.34～1.06)。结论：阿罗洛尔治疗原发性高血压与对照组比较具有相似的有效性及安全性。

关键词: 阿罗洛尔；阿尔马尔；高血压；Meta分析

Abstract:

Abstract:Objective To approach the efficacy and safety of arotinolol in treating essential hypertension. Methods The studies about arotinolol in treating essential hypertension were accessed by searching the Cochrane Central Register of Controlled Trials(Issue 3，2008)，MEDLINE(1991 to March 2009)，EMbase(1991 to March 2009)，CBMdisc(1991 to March 2009)，and CNKI(1994 to March 2009)．The relevant journals and conference proceedings also hand searched．Randomized controlled trials (RCTs) in which arotinolol was used to treat patients with essential hypertension were collected．Then the retrieved studies according to predefined inclusion and exclusion criteria were screened，the quality of included studies was evaluated，and Meta analysis was performed by using RevMan 4.2 software． Results A total of 176 articles were found and 6 of which were finally included.In homogeneity test：χ2=4.41，df=7，P=0.73(efficacy)；χ2=2.96，df=4，P=0.56 (safety).In combined test，Z=0.64（P=0.52），OR=1.17，OR95％CI (0.72-1.85) (efficacy)；Z=1.75（P=0.08），OR=0.60，OR95％CI (0.34-1.06) (safety).Conclusion There is no significant difference in efficacy and safety between arotinolol and control group in treating essential hypertension.

Key words: arotinolol;almarl； hypertension；Mata analysis
〖BF〗〖LM〗

中图分类号:

R972.4

杜冰, 秦玲, 崔文鹏. 阿罗洛尔治疗原发性高血压的Meta分析[J]. J4, 2009, 35(5): 949-954.

DU Bing, QIN Ling, CUI Wen-Feng. Mata analysis on arotinolol in treatment of essential hypertension[J]. J4, 2009, 35(5): 949-954.